The brand of pharmaceutical firm Novo Nordisk is displayed in entrance of its places of work in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026.
Tom Little | Reuters
The Meals and Drug Administration on Thursday authorised a higher-dose model of Novo Nordisk‘s blockbuster weight reduction injection Wegovy, as the corporate pushes to win again market share from chief rival Eli Lilly.
Novo expects to launch the upper, 7.2-milligram dose of Wegovy in April. The Danish drugmaker is positioning that model to raised compete with Lilly’s weight problems drug Zepbound, which has confirmed to be simpler at selling weight reduction than the usual, 2.4-milligram dose of Wegovy.
That increased efficacy has helped Zepbound turn into the popular weight problems medicine amongst prescribers and sufferers, despite the fact that it entered the U.S. market later than Wegovy, and has solidified Lilly’s place because the dominant participant within the house.
The high-dose Wegovy helped sufferers with weight problems lose a median 20.7% of their weight after 72 weeks in a section three trial. The usual dose of Wegovy has proven round 15% weight reduction on common in medical trials.
“I believe it actually makes it extra aggressive, and it actually reduces the delta there,” Dr. Jason Brett, principal U.S. medical head at Novo Nordisk, mentioned in an interview Thursday forward of the approval.
“However much more importantly, I believe it simply offers sufferers an alternative choice if they don’t seem to be reaching their targets, and attaining a few of these increased weight losses for sure sufferers,” he added.
In a separate section three trial on sufferers with weight problems and Kind 2 diabetes, high-dose Wegovy demonstrated a median weight lack of 14.1%. Individuals with diabetes sometimes have a tougher time losing a few pounds than individuals with out the situation.
It marks the primary approval of a GLP-1 remedy below the FDA’s new nationwide precedence voucher plan that goals to chop drug assessment occasions to 1 to 2 months for firms the company says are supporting U.S. nationwide well being priorities. The FDA launched the pilot plan in June.
